GSH‐Activated Porphyrin Sonosensitizer Prodrug for Fluorescence Imaging‐Guided Cancer Sonodynamic Therapy
Advanced Functional Materials · 2023-08 · 33 (32)
DOI: 10.1002/adfm.202300348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 05.05.2023. Verfasst von Caiting Deng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Engineering, Department of Biophysics, School of Basic Medical Science, Health Science Center, Xi'an Jiaotong University, No. 76…. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Natural Science Foundation of China, Natural Science Foundation of Shaanxi Province.
Abstract (Originalsprache)
Sonodynamic therapy (SDT), which uses ultrasound to trigger a sonosensitizer to generate reactive oxygen species (ROS), is a promising form of cancer therapy with outstanding tissue penetration depth. However, the sonosensitizer may inevitably spread to surrounding healthy tissue beyond the tumor, resulting in undesired side effects under an ultrasound stimulus. Herein, as glutathione (GSH) is overexpressed in the tumor microenvironment, a GSH‐activatable sonosensitizer prodrug is designed by attaching a quencher to tetraphydroxy porphyrin for tumor therapy. The prodrug exhibits poor fluorescence and low ROS generation capacity under ultrasound irradiation, but it also showed that it can be activated by GSH to simultaneously switch on fluorescence emission and ROS generation capability at the tumor site. Compared with the non‐quenched sonosensitizer, the designed prodrug exhibits significantly higher tumor/healthy organ fluorescence ratios, due to the specific fluorescence and ROS activation by overexpressed GSH in the tumor. Finally, the prodrug exhibits efficient tumor growth inhibition under ultrasound irradiation, further demonstrating its promise as a GSH‐activated sonosensitizer prodrug for highly effective cancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Medical Engineering, Department of Biophysics, School of Basic Medical Science, Health Science Center, Xi'an Jiaotong University, No. 76 Yanta West Road, Xi'an 710061, Shaanxi, China.
- School of Public Health, Health Science Center, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an 710061 Shaanxi, China.
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
Förderung
- NCI NIH HHS
- National Natural Science Foundation of China
- Natural Science Foundation of Shaanxi Province
Zitieren
APA
Deng, C., Zheng, M., Han, S., Wang, Y., Xin, J., Aras, O., Cheng, L., & An, F. (2023). GSH‐Activated Porphyrin Sonosensitizer Prodrug for Fluorescence Imaging‐Guided Cancer Sonodynamic Therapy. Advanced Functional Materials, 33(32). https://doi.org/10.1002/adfm.202300348
Vancouver
Deng C, Zheng M, Han S, Wang Y, Xin J, Aras O, et al. GSH‐Activated Porphyrin Sonosensitizer Prodrug for Fluorescence Imaging‐Guided Cancer Sonodynamic Therapy. Advanced Functional Materials. 2023;33(32). doi:10.1002/adfm.202300348
BibTeX
@article{Deng2023,
author = {Deng, Caiting and Zheng, Meichen and Han, Shupeng and Wang, Yuanjie and Xin, Jingqi and Aras, Omer and Cheng, Liang and An, Feifei},
title = {GSH‐Activated Porphyrin Sonosensitizer Prodrug for Fluorescence Imaging‐Guided Cancer Sonodynamic Therapy},
journal = {Advanced Functional Materials},
year = {2023},
volume = {33},
number = {32},
doi = {10.1002/adfm.202300348}
}
EUVIMED